A Phase 1/2 interventional study of NanoFlu and Fluzone HD - Day 0 in Influenza, sponsored by Novavax. Completed at 3 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-21.
Sponsored by Novavax · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Influenza, Human by Novavax — none open to participants now, none under way, none of them phase 3. Influenza, Human · Novavax.
Among the 18 studies in Influenza, Human by Novavax, this one is the 12th largest by enrollment, is the only one that started in 2017, is one of 3 in phase 1/2, and was the 12th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →None of the 18 studies in Influenza, Human by Novavax is open now. The open studies under Influenza, Human, anywhere →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 4
First in 2007; this study’s year is marked. 1 started in 2017.
This study's enrollment of 330 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 367 across the 18 interventional studies. Of the 15 that completed or were terminated, 3 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novavax is the lead sponsor of 47 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Influenza, Human by Novavax, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase 1/2, randomized, observer-blinded, active-controlled trial to assess the Safety and Tolerability of a Recombinant Trivalent Nanoparticle Influenza Vaccine (Tri-NIV) with Matrix M1™ Adjuvant in Healthy Older Adults ≥ 60 Years of Age
Study tNIV-E-101 a randomized, observer-blinded, active-controlled trial designed to evaluate the safety and immunogenicity of Novavax's insect cell-derived, egg-free, influenza vaccine (Tri-NIV) based on recombinant HA nanoparticle antigens, representing the 3 major influenza types/subtypes recommended for inclusion in the 2017 - 2018 seasonal influenza vaccine by the World Health Organization (WHO) and the Center for Biologics Evaluation and Research (CBER) Approximately 330 eligible subjects were enrolled and randomized into 1 of 3 treatment groups Each group consisted of approximately 110 subjects total, stratified by age, gender, and history of receipt of the 2016 - 17 influenza vaccine. On Day 0, subjects in Groups A and B were administered an IM injection of NanoFlu at one of two dose levels; subjects in Group C received the preconfigured comparator (Fluzone HD) at the manufacturer's recommended dose and volume. On Day 21, all Group A and B subjects were administered a rescue injection with a licensed seasonal influenza vaccine. In contrast, all Group C subjects were administered an injection with a sterile saline placebo to maintain the trial blind. Trial follow-up for each subject spanned approximately 1 year from Day 0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose NanoFlu - Day 0; Fluzone HD - Day 21
Biological: NanoFlu · Biological: Fluzone HD - Day 21
High dose NanoFlu - Day 0; Fluzone HD - Day 21
Biological: NanoFlu · Biological: Fluzone HD - Day 21
Fluzone HD - Day 0; Saline - Day 21
Biological: Fluzone HD - Day 0 · Other: Saline - Day 21
Vaccine
Vaccine
Vaccine
Placebo
Number of Participants With All Adverse Events (AEs), Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Significant New Medical Conditions (SNMCs).
Number of participants that reported all adverse event (AE) profile (including adverse changes in clinical laboratory parameters) ; medically-attended adverse event (MAE), serious adverse event (SAE), and significant new medical condition (SNMC) post dosing.
Time frame: Day 0 - Day 21 post dosing
Number of Participants With Solicited Local and Systemic AEs
Number of participants with solicited local and systemic adverse events over the 7 days post-injection
Time frame: Day 0 - Day 6 post-dosing
Geometric Mean Titers (GMT) Specific for the Hemagglutinin (HA) Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the Hemagglutination Inhibition (HAI) Assay.
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as GMTs.
Time frame: Day 0 - Day 21 post dosing
Geometric Mean Ratio (GMR) Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as GMR.
Time frame: Day 0 - Day 21 post dosing
Seroconversion Rate (SCR) Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as SCRs.
Time frame: Day 0 - Day 21 post dosing
Number of Participants With Seroprotection Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as SPRs. Seroprotection rate (SPR) - defined as the number of subjects with an HAI titer ≥ 1:40.
Time frame: Day 0 - Day 21 post dosing
Geometric Mean Titers (GMT) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay
The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as GMTs.
Time frame: Day 0 - Day 21
Geometric Mean Ratio (GMR) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay
The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as GMRs.
Time frame: Day 0 - Day 21
Seroconversion Rate (SCR) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay
The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as SCRs.
Time frame: Day 0 - Day 21
Number of Participants With Seroprotection Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay
The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as SPRs. Seroprotection rate (SPR) - defined as the percentage of subjects with an HAI titer ≥ 1:40.
Time frame: Day 0 - Day 21
Geometric Mean Titers (GMT) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as GMTs.
Time frame: Day 0 - Day 21 post dosing
Geometric Mean Ratio (GMR) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as GMRs.
Time frame: Day 0 - Day 21
Seroconversion Rate (SCR) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as SPRs.
Time frame: Day 0 - Day 21
Participants took part in a study conducted at 3 different clinical sites from September 18, 2017 to October 29, 2018.
| Milestone | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| Started | 109 | 111 | 110 |
| Completed | 109 | 111 | 110 |
| Not completed | 0 | 0 | 0 |
Number of participants that reported all adverse event (AE) profile (including adverse changes in clinical laboratory parameters) ; medically-attended adverse event (MAE), serious adverse event (SAE), and significant new medical condition (SNMC) post dosing.
| participants | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| MAE's | 9 | 6 | 2 |
| SAE's | 0 | 1 | 0 |
| SNMC's | 0 | 1 | 0 |
| All AEs (21 days post-injection) | 40 | 52 | 51 |
Number of participants with solicited local and systemic adverse events over the 7 days post-injection
| participants | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| Solicited Local AE's (Day 0 to Day 6) | 15 | 26 | 30 |
| Solicited Systemic AE's (Day 0 to Day 6) | 23 | 24 | 20 |
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as GMTs.
| titers | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| Day 0 (A/Michigan/45/2015 (H1N1)) | 39 (31 to 48) | 34 (27 to 42) | 31 (25 to 38) |
| Day 21 (A/Michigan/45/2015 (H1N1)) | 95 (75 to 121) | 130 (102 to 166) | 139.1 (112 to 174) |
| Day 0 (A/HongKong/4801/2014 (H3N2) ) | 26 (21 to 33) | 21 (17 to 27) | 26 (21 to 33) |
| Day 21 (A/HongKong/4801/2014 (H3N2) ) | 62 (48 to 79) | 75 (59 to 94) | 94 (74 to 119) |
| Day 0 (B/Brisbane/60/2008 (Victoria Lineage)) | 19 (15 to 23) | 18 (15 to 22) | 15 (12 to 17) |
| Day 21 (B/Brisbane/60/2008 (Victoria Lineage)) | 24 (20 to 30) | 29 (24 to 35) | 37 (31 to 46) |
| Day 0 (A/California/07/2009 (H1N1)) | 65 (53 to 80) | 59 (48 to 73) | 52 (42 to 64) |
| Day 21 (A/California/07/2009 (H1N1) ) | 143 (116 to 176) | 194 (156 to 242) | 206 (169 to 222) |
| Day 0 (A/Texas/50/2012 (H3N2) ) | 197 (155 to 251) | 160 (123 to 207) | 196 (151 to 253) |
| Day 21 (A/Texas/50/2012 (H3N2) ) | 429 (352 to 523) | 485 (397 to 592) | 470 (382 to 577) |
| Day 0 (A/Switzerland/9715293/2013 (H3N2)) | 65 (50 to 83) | 55 (43 to 71) | 60 (47 to 78) |
| Day 21 (A/Switzerland/9715293/2013 (H3N2)) | 159 (128 to 198) | 187 (150 to 234) | 151 (122 to 188) |
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as GMR.
| Ratio | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| Day 21 (A/Michigan/45/2015 (H1N1)) | 2.47 (2.05 to 2.98) | 3.86 (3.07 to 4.85) | 4.55 (3.60 to 5.75) |
| Day 21 (A/HongKong/4801/2014 (H3N2) ) | 2.35 (1.94 to 2.84) | 3.49 (2.78 to 4.37) | 3.57 (2.87 to 4.45) |
| Day 21 (B/Brisbane/60/2008 (Victoria Lineage)) | 1.30 (1.16 to 1.44) | 1.57 (1.39 to 1.78) | 2.56 (2.10 to 3.11) |
| Day 21 (A/California/07/2009 (H1N1) ) | 2.20 (1.87 to 2.59) | 3.29 (2.67 to 4.05) | 3.94 (3.16 to 4.92) |
| Day 21 (A/Texas/50/2012 (H3N2) ) | 2.17 (1.83 to 2.58) | 3.04 (2.48 to 3.72) | 2.40 (2.01 to 2.87) |
| Day 21 (A/Switzerland/9715293/2013 (H3N2)) | 2.46 (2.04 to 2.95) | 3.38 (2.72 to 4.21) | 2.51 (2.08 to 3.02) |
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as SCRs.
| participants | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| Day 21 (A/Michigan/45/2015 (H1N1)) | 34 | 49 | 54 |
| Day 21 (A/HongKong/4801/2014 (H3N2) ) | 24 | 34 | 43 |
| Day 21 (B/Brisbane/60/2008 (Victoria Lineage)) | 5 | 13 | 29 |
| Day 21 (A/California/07/2009 (H1N1) ) | 24 | 45 | 53 |
| Day 21 (A/Texas/50/2012 (H3N2) ) | 21 | 38 | 29 |
| Day 21 (A/Switzerland/9715293/2013 (H3N2)) | 28 | 43 | 30 |
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as SPRs. Seroprotection rate (SPR) - defined as the number of subjects with an HAI titer ≥ 1:40.
| participants | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| Day 0 (A/Michigan/45/2015 (H1N1)) | 65 | 63 | 57 |
| Day 21 (A/Michigan/45/2015 (H1N1)) | 93 | 96 | 98 |
| Day 0 (A/HongKong/4801/2014 (H3N2) ) | 51 | 45 | 45 |
| Day 21 (A/HongKong/4801/2014 (H3N2) ) | 76 | 79 | 89 |
| Day 0 (B/Brisbane/60/2008 (Victoria Lineage)) | 31 | 30 | 19 |
| Day 21 (B/Brisbane/60/2008 (Victoria Lineage)) | 42 | 53 | 57 |
| Day 0 (A/California/07/2009 (H1N1) ) | 80 | 77 | 74 |
| Day 21 (A/California/07/2009 (H1N1) ) | 98 | 102 | 104 |
| Day 0 (A/Texas/50/2012 (H3N2) ) | 98 | 96 | 98 |
| Day 21 (A/Texas/50/2012 (H3N2) ) | 109 | 110 | 108 |
| Day 0 (A/Switzerland/9715293/2013 (H3N2)) | 79 | 71 | 73 |
| Day 21 (A/Switzerland/9715293/2013 (H3N2)) | 101 | 103 | 100 |
The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as GMTs.
| titers | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| A/Michigan/45/2015 (H1N1) : Day 0 | 69 (61 to 78) | 66 (59 to 74) | 65 (58 to 74) |
| A/Michigan/45/2015 (H1N1): Day 21 | 146 (120 to 178) | 210 (171 to 258) | 171 (141 to 206) |
| A/HongKong/4801/2014 (H3N2) : Day 0 | 60 (53 to 69) | 58 (51 to 66) | 62 (53 to 74) |
| A/HongKong/4801/2014 (H3N2) : Day 21 | 127 (103 to 157) | 159 (126 to 201) | 116 (91 to 147) |
The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as GMRs.
| Ratio | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| A/Michigan/45/2015 (H1N1) : Day 21 | 2.13 (1.83 to 2.48) | 3.17 (2.61 to 3.85) | 2.61 (2.21 to 3.09) |
| A/HongKong/4801/2014 (H3N2) : Day 21 | 2.10 (1.75 to 2.53) | 2.74 (2.22 to 3.38) | 1.85 (1.56 to 2.20) |
The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as SCRs.
| participants | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| A/Michigan/45/2015 (H1N1): Day 21 | 27 (17.0 to 34.0) | 45 (31.6 to 50.7) | 40 (27.7 to 46.5) |
| A/Michigan/45/2015 (H1N1) : Day 21 | 29 (18.6 to 35.9) | 38 (25.7 to 44.2) | 25 (15.4 to 32.0) |
The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as SPRs. Seroprotection rate (SPR) - defined as the percentage of subjects with an HAI titer ≥ 1:40.
| percentage of participants | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| A/Michigan/45/2015 (H1N1) : Day 0 | 99.1 (95.0 to 100.0) | 98.2 (93.6 to 99.8) | 97.2 (92.2 to 99.4) |
| A/Michigan/45/2015 (H1N1) : Day 21 | 100.0 (96.7 to 100.0) | 100 (96.7 to 100.0) | 99.1 (95.0 to 100.0) |
| A/HongKong/4801/2014 (H3N2) : Day 0 | 97.2 (92.2 to 99.4) | 96.4 (91.0 to 99.0) | 90.8 (83.8 to 95.5) |
| A/HongKong/4801/2014 (H3N2) : Day 21 | 100.0 (96.7 to 100.0) | 98.2 (93.6 to 99.8) | 94.5 (88.4 to 98.0) |
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as GMTs.
| titers | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| Day 0 (A/Switzerland/9715293/2013 (H3N2)) | 1696 (1292 to 2227) | 1258 (954 to 1658) | 1400 (1046 to 1873) |
| Day 21 (A/Switzerland/9715293/2013 (H3N2)) | 4419 (3391 to 5758) | 5223 (3997 to 6824) | 3011 (2268 to 3997) |
| Day 0 (A/Texas/50/2012 (H3N2)) | 3660 (2803 to 4778) | 2768 (2142 to 3577) | 3307 (2484 to 4402) |
| Day 21 (A/Texas/50/2012 (H3N2)) | 9204 (7165 to 11822) | 10495 (8213 to 13410) | 8383 (6409 to 10964) |
| Day 0 (A/Singapore/INFIMH-16-0019/2016 (H3N2) | 587 (461 to 748) | 437 (349 to 547) | 489 (367 to 651) |
| Day 21 (A/Singapore/INFIMH-16-0019/2016 (H3N2) | 1469 (1113 to 1940) | 1640 (1254 to 2146) | 1905 (1434 to 2531) |
| Day 0 (A/Michigan/45/2015 (H1N1)) | 411 (327 to 516) | 342 (269 to 436) | 334 (259 to 432) |
| Day 21 (A/Michigan/45/2015 (H1N1)) | 1414 (1070 to 1868) | 2005 (1485 to 2708) | 1741 (1313 to 2309) |
| Day 0 (A/HongKong/4801/2014 (H3N2) ) | 1239 (957 to 1605) | 891 (698 to 1137) | 1081 (816 to 1433) |
| Day 21 (A/HongKong/4801/2014 (H3N2) ) | 3359 (2577 to 4378) | 3791 (2906 to 4944) | 4455 (3426 to 5793) |
| Day 0 (B/Brisbane/60/2008 (Victoria Lineage)) | 167 (129 to 216) | 174 (137 to 220) | 154 (124 to 193) |
| Day 21 (B/Brisbane/60/2008 (Victoria Lineage)) | 287 (228 to 361) | 354 (285 to 439) | 425 (341 to 529) |
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as GMRs.
| Ratio | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| Day 21 (A/Switzerland/9715293/2013 (H3N2)) | 2.61 (2.13 to 3.19) | 4.15 (3.25 to 5.31) | 2.15 (1.82 to 2.55) |
| Day 21 (A/Texas/50/2012 (H3N2)) | 2.51 (2.04 to 3.10) | 3.79 (3.05 to 4.72) | 2.53 (2.09 to 3.07) |
| Day 21 (A/Singapore/INFIMH-16-0019/2016 (H3N2)) | 2.50 (1.99 to 3.15) | 3.76 (2.98 to 4.74) | 3.90 (3.09 to 4.92) |
| Day 21: A/Michigan/45/2015 (H1N1) | 3.44 (2.74 to 4.33) | 5.86 (4.45 to 7.72) | 5.21 (3.94 to 6.89) |
| Day 21: A/HongKong/4801/2014 (H3N2) | 2.71 (2.20 to 3.33) | 4.25 (3.34 to 5.42) | 4.12 (3.26 to 5.20) |
| Day 21: B/Brisbane/60/2008 (Victoria Lineage) | 1.72 (1.48 to 2.00) | 2.03 (1.70 to 2.43) | 2.75 (2.19 to 3.47) |
The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as SPRs.
| participants | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| Day 21 (A/Switzerland/9715293/2013 (H3N2)) | 22 (13.1 to 29.0) | 45 (31.6 to 50.7) | 20 (11.6 to 26.9) |
| Day 21 (A/Texas/50/2012 (H3N2)) | 26 (16.2 to 33.0) | 47 (33.3 to 52.5) | 28 (17.8 to 34.9) |
| Day 21 (A/Singapore/INFIMH-16-0019/2016 (H3N2) | 27 (17.0 to 34.0) | 38 (25.7 to 44.2) | 43 (30.2 to 49.3) |
| Day 21: A/Michigan/45/2015 (H1N1) | 33 (21.8 to 39.8) | 53 (38.6 to 57.9) | 50 (36.3 to 55.7) |
| Day 21: A/HongKong/4801/2014 (H3N2) | 28 (17.8 to 34.9) | 43 (29.9 to 48.9) | 48 (34.5 to 53.9) |
| Day 21: B/Brisbane/60/2008 (Victoria Lineage) | 13 (6.5 to 19.5) | 18 (10.0 to 24.6) | 23 (13.9 to 30.0) |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | 0/109 (0%) | 7/109 (6.4%) | 32/109 (29.4%) |
| Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | 0/111 (0%) | 11/111 (9.9%) | 27/111 (24.3%) |
| Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. | 0/110 (0%) | 8/110 (7.3%) | 28/110 (25.5%) |
| Event | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| CEREBROVASCULAR ACCIDENTNervous system disorders | 0/109 | 2/111 | 0/110 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/109 | 0/111 | 1/110 |
| CHEST DISCOMFORTGeneral disorders | 1/109 | 0/111 | 0/110 |
| PELVIC ABSCESSInfections and infestations | 1/109 | 0/111 | 0/110 |
| SEROMAInjury, poisoning and procedural complications | 1/109 | 0/111 | 0/110 |
| PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/109 | 0/111 | 0/110 |
| SYNCOPENervous system disorders | 1/109 | 0/111 | 0/110 |
| NEPHROLITHIASISRenal and urinary disorders | 1/109 | 0/111 | 0/110 |
| PYREXIAGeneral disorders | 0/109 | 0/111 | 1/110 |
| BETA HAEMOLYTIC STREPTOCOCCAL INFECTIONInfections and infestations | 0/109 | 0/111 | 1/110 |
| Event | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. |
|---|---|---|---|
| BRONCHITISInfections and infestations | 11/109 | 9/111 | 6/110 |
| BLOOD PRESSURE SYSTOLIC INCREASEDInvestigations | 11/109 | 4/111 | 8/110 |
| SINUSITISInfections and infestations | 4/109 | 5/111 | 7/110 |
| HEADACHENervous system disorders | 2/109 | 7/111 | 1/110 |
| HYPERTENSIONVascular disorders | 4/109 | 2/111 | 6/110 |
330 participants were randomized to 1 of 3 treatment groups based on age, gender, and history of receipt of the 2016 - 17 influenza vaccine.
| Age, Customized(Participants) | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. | Total |
|---|---|---|---|---|
| 60 to < 75 years | 90 | 91 | 90 | 271 |
| ≥ 75 years | 19 | 20 | 20 | 59 |
| Sex: Female, Male(Participants) | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. | Total |
|---|---|---|---|---|
| Female | 58 | 60 | 57 | 175 |
| Male | 51 | 51 | 53 | 155 |
| Ethnicity (NIH/OMB)(Participants) | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 3 |
| Not Hispanic or Latino | 108 | 110 | 109 | 327 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 17 | 13 | 9 | 39 |
| White | 91 | 98 | 99 | 288 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| History of Prior Flu Vaccinations(participants) | Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21 | Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21. | Total |
|---|---|---|---|---|
| Receipt of 2016 - 17 Flu Vaccine | 95 | 94 | 93 | 282 |
| Receipt of Flu Vaccine in Past 3 Years | 102 | 101 | 102 | 305 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Sep 2017 to primary completion in Mar 2018, 5 months.
Results were first posted in Dec 2022, 4 years 9 months after primary completion. A results delay was requested in Aug 2019.
Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 5 months is below that.
Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.